Zhongsheng Pharmaceutical (002317.SZ): Topline analysis data results obtained for the Phase III clinical trial of the Class 1 innovative drug RAY1225 injection for weight loss

Zhitong Finance APP News, Zhongsheng Pharmaceutical (002317.SZ) announced that the Phase III multicenter, randomized, double-blind, placebo-controlled clinical trial (REBUILDING-2) evaluating the safety and efficacy of RAY1225 Injection, a Class 1 innovative peptide drug independently developed by the company's holding subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as "Zhongsheng Ruichuang"), in overweight or obese participants, recently obtained top-line analysis data. Preliminary results show that RAY1225 Injection demonstrated positive efficacy and good safety in Chinese adult obese/overweight participants. The trial results are ideal and have achieved the expected goals.